BioMark Diagnostics Inc.
BMKDF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.64 | 0.68 | -0.79 | -0.31 |
| FCF Yield | -4.53% | -4.08% | -5.77% | -7.98% |
| EV / EBITDA | -15.14 | -27.85 | -13.02 | -13.47 |
| Quality | ||||
| ROIC | -86.93% | -140.54% | -345.20% | -339.16% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.57 | 0.69 | 0.50 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.16% | 54.88% | – | -44.95% |
| Free Cash Flow Growth | -11.12% | -7.31% | 27.19% | -56.46% |
| Safety | ||||
| Net Debt / EBITDA | 1.38 | -1.51 | -1.17 | -0.54 |
| Interest Coverage | -31.01 | -11.42 | -15.71 | -28.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 380.26 | 96.22 | 81.74 | 682.34 |